Last $0.75 SGD
Change Today +0.01 / 1.36%
Volume 3.2M
BIG On Other Exchanges
Symbol
Exchange
Singapore
OTC US
OTC US
Stuttgart
As of 5:04 AM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

biosensors international gro (BIG) Snapshot

Open
$0.74
Previous Close
$0.74
Day High
$0.75
Day Low
$0.74
52 Week High
05/26/14 - $1.04
52 Week Low
08/20/14 - $0.70
Market Cap
1.3B
Average Volume 10 Days
5.7M
EPS TTM
$0.02
Shares Outstanding
1.7B
EX-Date
07/31/13
P/E TM
26.6x
Dividend
$0.02
Dividend Yield
3.42%
Current Stock Chart for BIOSENSORS INTERNATIONAL GRO (BIG)

Related News

No related news articles were found.

biosensors international gro (BIG) Related Businessweek News

No Related Businessweek News Found

biosensors international gro (BIG) Details

Biosensors International Group, Ltd., an investment holding company, develops, manufactures, and markets various medical devices for interventional cardiology and critical care procedures in China, Japan, and internationally. The company operates in four segments: Interventional Cardiology, Critical Care, Cardiac Diagnostic, and Licensing Revenue. The Interventional Cardiology segment supplies proprietary drug-eluting stents, coronary bare-metal stents, accompanying stent delivery balloon catheter systems, angioplasty balloons, and catheters under the BioMatrix Flex, BioMatrix NeoFlex, Axxess, BioFreedom, Chroma, Gazelle, Biostream, Biopath, and Powerline brands. The Critical Care segment supplies catheter systems and related accessories that are used in surgeries, and intensive care treatment and monitoring procedures. This segment offers ACCUTRANS, a disposable blood pressure transducer system; BIOTRANS, a re-usable blood pressure transducer; Multi-Lumen central venous catheters for infant and adult patients to administer medication or fluids, obtain blood tests, and directly obtain cardiovascular measurements; Thermodilution and Pulmonary Artery catheters for pulmonary artery monitoring; Bipolar Pacing catheters for temporary transvenous cardiac pacing to support critical procedures in the catherization lab, CCU, and emergency room settings; Embolectomy catheters; and BIOTRAY devices. The Cardiac Diagnostic segment supplies medical imaging and clinical applications. The Licensing Revenue segment is engaged in the licensing of its proprietary drug-eluting stent technology and intellectual property. The company was founded in 1990 and is headquartered in Singapore.

Founded in 1990

biosensors international gro (BIG) Top Compensated Officers

Founder, Executive Chairman, Interim Chief Ex...
Total Annual Compensation: $1.4M
Chief Operating Officer and Executive Directo...
Total Annual Compensation: $94.0K
President of Cardiovascular Business Unit
Total Annual Compensation: $2.5M
Chief Technology Officer
Total Annual Compensation: $988.0K
Compensation as of Fiscal Year 2014.

biosensors international gro (BIG) Key Developments

Biosensors International Group, Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2014

Biosensors International Group, Ltd. reported consolidated earnings results for the first quarter ended June 30, 2014. Total revenue was $80,211,000 compared to $76,666,000 a year ago. Profit from operations was $14,843,000 compared to $18,737,000 a year ago. Profit before exceptional and non-operating items was $13,161,000 compared to $16,918,000 a year ago. Profit before tax was $8,526,000 compared to $12,546,000 a year ago. Net profit for the period attributable to equity holders of the company was $9,871,000 or 0.58 cents diluted per share compared to $12,102,000 or 0.69 cents diluted per share a year ago. Net assets per share was 75.78 cents compared to 73.84 cent a year ago. Net cash generated from operating activities was $16,555,000 compared to $4,753,000 a year ago. Purchase of property, plant and equipment was $15,547,000 compared to $4,192,000 a year ago. Purchase of intangible assets was $1,415,000 compared to $1,422,000 a year ago.

Biosensors Mulls Acquisitions

Biosensors International Group, Ltd. (SGX:B20) is looking for acquisitions. Yoh-Chie Lu, Biosensors' Chairman and interim Chief Executive Officer said, "We will continue to actively identify new growth opportunities, including acquiring new businesses and other ways to improve our overall performance. We firmly believe that we have the right combination of leadership, strategy and resources to propel us forward and enable us to become a leading international medical device player".

Biosensors International Group, Ltd., Q1 2015 Earnings Call, Aug 06, 2014

Biosensors International Group, Ltd., Q1 2015 Earnings Call, Aug 06, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIG:SP $0.75 SGD +0.01

BIG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $12.38 USD -0.06
View Industry Companies
 

Industry Analysis

BIG

Industry Average

Valuation BIG Industry Range
Price/Earnings 26.3x
Price/Sales 3.0x
Price/Book 0.8x
Price/Cash Flow 26.8x
TEV/Sales 0.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOSENSORS INTERNATIONAL GRO, please visit www.biosensors.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.